Study guide
5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
Key Takeaways Explain This Topic AI
Hidradenitis suppurativa is a chronic inflammatory follicular disease with painful nodules, abscesses, and draining tunnels in the axillae, groins, and anogenital region, affecting about 1% of Europeans in many estimates.
The IHS4 severity score equals the number of nodules plus 2 times abscesses plus 3 times draining tunnels, with 3 or less mild, 4 to 10 moderate, and 11 or more severe.
Adalimumab, secukinumab, and bimekizumab are approved in the EU for moderate-to-severe hidradenitis suppurativa after inadequate response to conventional systemic therapy.
Oral clindamycin 300 mg twice daily with rifampicin 300 mg twice daily for about 10 to 12 weeks is a standard European regimen for moderate hidradenitis suppurativa.
Primary focal hyperhidrosis is bilateral, symmetric, starts before about 25 years of age, and stops during sleep, whereas generalised or nocturnal sweating needs a search for secondary causes.
Last updated: September 2026
- 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
- Hidradenitis Suppurativa (HS)
HS (acne inversa) is a chronic, inflammatory, recurrent, and debilitating disease of the hair follicle. It usually starts after puberty and causes painful deep nodules, abscesses, and draining tunnels (sinus tracts) in skin folds. It is often diagnosed late and has a heavy impact on quality of life, work, and mood.
Epidemiology and Pathogenesis
Prevalence: estimates vary widely; about 1% is commonly quoted for Europe. In Europe, women are affected more often than men.
Risk factors: smoking and obesity are the strongest modifiable factors. There is often a family history.
Pathogenesis: infundibular hyperkeratosis blocks the follicle, which dilates and ruptures. The contents trigger inflammation involving TNF-alpha, IL-1, and IL-17 , followed by tunnel formation and scarring. It is not primarily an infection or a disease of apocrine glands.
Genetics: some familial cases carry mutations in gamma-secretase genes ( NCSTN , PSENEN , PSEN1 ).
Associations: Crohn disease, spondyloarthritis, metabolic syndrome, polycystic ovary syndrome, depression, and the follicular occlusion tetrad (HS, acne conglobata, dissecting cellulitis of the scalp, and pilonidal sinus). Syndromic forms include PASH (pyoderma gangrenosum, acne, suppurative hidradenitis) and PAPASH (adding pyogenic arthritis).
Complications: anaemia, secondary amyloidosis, lymphoedema, and squamous cell carcinoma in long-standing gluteal and perineal disease, more often in men.
Diagnosis
Diagnosis is clinical and needs all three:
Typical lesions: deep painful nodules, abscesses, draining tunnels, bridged scars, and double-ended comedones .
Typical sites: axillae, groins, inner thighs, perineal and perianal skin, buttocks, and inframammary folds.
Chronicity and recurrence: for example, at least two flares within 6 months.
Severity Scores
- Tool Definition
- Hurley I Single or multiple abscesses without tunnels or scarring
- Hurley II Recurrent abscesses with tunnels and scarring; single or multiple widely separated lesions
- Hurley III Diffuse involvement, with multiple interconnected tunnels and abscesses across the whole area
- IHS4 (Nodules × 1) + (Abscesses × 2) + (Draining tunnels × 3); ≤ 3 mild, 4–10 moderate, ≥ 11 severe
HiSCR Response measure: at least 50% fewer abscesses and inflammatory nodules, with no increase in abscesses or draining tunnels
European Treatment Approach
- Situation Options
- All patients Stop smoking, lose weight, pain control, dressings, treat depression; screen for comorbidity
Mild (Hurley I, few lesions) Topical clindamycin 1%; intralesional triamcinolone for painful nodules; antiseptic washes
- Mild-to-moderate, widespread Oral tetracycline (doxycycline or lymecycline) for about 12 weeks
- Moderate Oral clindamycin 300 mg twice daily + rifampicin 300 mg twice daily for about 10–12 weeks
Moderate-to-severe, not responding Biologics: adalimumab (160 mg at week 0, 80 mg at week 2, then 40 mg weekly or 80 mg every other week); secukinumab (IL-17A); bimekizumab (IL-17A and IL-17F)
Other options Acitretin, dapsone, antiandrogens or metformin in women, and intravenous ertapenem for severe flares in specialist centres
Surgery (any stage for fixed lesions) Deroofing of tunnels; wide local excision; CO2 laser excision. Simple incision and drainage relieves pain from an acute abscess but is followed by high recurrence
Rifampicin is a strong enzyme inducer . It reduces the effect of hormonal contraception and many other drugs, and it colours urine and tears orange. Adalimumab is licensed in the EU for adults and adolescents from 12 years with active moderate-to-severe HS and an inadequate response to conventional systemic therapy. The best results come from combining medical treatment with surgery for established tunnels.
- Hyperhidrosis
- Primary Focal Hyperhidrosis
Excessive sweating beyond thermoregulatory need, usually of the axillae, palms, soles, or face . Typical features are:
- bilateral and symmetric sweating;
- onset before about 25 years ;
- at least one episode a week;
- no sweating during sleep ;
- a positive family history;
impaired daily activities.
Severity is often graded with the Hyperhidrosis Disease Severity Scale (HDSS) from 1 (never noticeable) to 4 (intolerable, always interfering). The Minor starch-iodine test maps the sweating area before botulinum toxin.
Secondary Hyperhidrosis
Generalised, asymmetric, or nocturnal sweating, or onset in later adult life, suggests a secondary cause: fever and infection (tuberculosis, endocarditis), hyperthyroidism, diabetes and hypoglycaemia, phaeochromocytoma, carcinoid, lymphoma and other cancers, menopause, anxiety, neurological disease, and drugs (antidepressants, opioids, cholinergic drugs). Gustatory sweating after parotid surgery is Frey syndrome .
Treatment Ladder for Primary Hyperhidrosis
- Step Treatment Notes
- 1 Topical aluminium chloride hexahydrate (10–30%) at night Irritation is the main side effect
2 Topical anticholinergic (glycopyrronium bromide cream for axillae) Approved in several EU countries for severe primary axillary hyperhidrosis in adults
- 3 Tap-water iontophoresis First choice for palms and soles
- 4 Botulinum toxin type A injections Effect lasts about 4–9 months; for palms, risk of temporary hand weakness
- 5 Oral anticholinergics (oxybutynin, glycopyrronium) Off-label; dry mouth, blurred vision, urinary retention
- 6 Microwave thermolysis or local surgery (axillae) Specialist centres
7 Endoscopic thoracic sympathectomy Last resort for palmar disease; compensatory hyperhidrosis elsewhere is common and can be worse
Other Sweat Gland Disorders
Disorder Gland Features
Miliaria crystallina Eccrine (duct blocked in stratum corneum) Clear 1–2 mm vesicles like water drops after fever or heat, no inflammation
Miliaria rubra (prickly heat) Eccrine (blockage deeper in epidermis) Itchy red papules in covered areas in hot, humid weather
Miliaria profunda Eccrine (dermal level) Flesh-coloured papules after repeated miliaria rubra; can cause heat exhaustion
- Fox-Fordyce disease Apocrine Itchy follicular papules in the axillae of young women ("apocrine miliaria")
- Bromhidrosis Apocrine (mainly) Offensive odour from bacterial breakdown of sweat
- Chromhidrosis Apocrine Coloured sweat (lipofuscin)
Anhidrosis / hypohidrosis Eccrine Hypohidrotic ectodermal dysplasia (usually X-linked EDA ), Fabry disease, Ross syndrome, neuropathy, and drugs; risk of heat stroke